We have located links that may give you full text access.
English Abstract
Journal Article
[Biochemical control after conformal, 3 dimensional radiotherapy of prostatic carcinoma].
BACKGROUND: To evaluate biochemical control after 3-D radiation therapy of prostate cancer.
PATIENTS AND METHODS: 180 patients with a median follow-up of 30.5 months (12-67 months) were evaluated. Median dose to the prostate was 70 Gy. 72% of the patients received short-term neoadjuvant hormonal therapy and 28% received radiation therapy alone. Biochemical failure was defined according to the ASTRO consensus criteria.
RESULTS: Pre-treatment PSA levels were higher for patients with combined therapy as compared to radiation alone (median: 13.5 ng/ml vs. 8.8 ng/ml, p = 0.003). Biochemical no-evidence of disease (bNED) survival for all patients was 73% at 3 years. In univariate analysis the following factors were predictive for bNED survival: pre-treatment PSA (< or = 20 ng/ml vs. > 20 ng/ml; 3-years bNED 82% vs. 49%; p < 0.001); age (< 72 years vs. > or = 72 years; 3-years bNED 69% vs. 78%; p = 0.049); tumor differentiation (grade 1 vs. grade 2 vs. grade 3; 3-years bNED 89% vs. 74% vs. 46%; p = 0.002); PSA-nadir value (< or = 0.5 ng/ml vs. > 0.5 ng/ml; 3-years bNED 84% vs. 51%; p < 0.001); time to PSA-nadir (< or = 12 months vs. > 12 months; 3-years bNED 66% vs. 82%; p = 0.04). There was a trend to a lower bNED survival in patients with T3/T4 disease (T1/T2 vs. T3/T4; 3-years bNED 80% vs. 60%; p = 0.059). Neoadjuvant hormonal therapy or dose to the prostate had no significant impact on bNED survival. In multivariate analysis pretreatment PSA, tumor differentiation, PSA-nadir, time to PSA-nadir and age were independent prognostic factors.
CONCLUSIONS: Despite of having higher initial PSA-values patients treated with conformal radiotherapy and short-term neoadjuvant hormonal therapy had the same bNED survival as patients treated with conformal radiotherapy alone. Patients with initial PSA values above 20 ng/ml, with T3 or T4 disease or with poorly differentiated tumors had a low biochemical control. For this group of patients intensified therapy should be considered.
PATIENTS AND METHODS: 180 patients with a median follow-up of 30.5 months (12-67 months) were evaluated. Median dose to the prostate was 70 Gy. 72% of the patients received short-term neoadjuvant hormonal therapy and 28% received radiation therapy alone. Biochemical failure was defined according to the ASTRO consensus criteria.
RESULTS: Pre-treatment PSA levels were higher for patients with combined therapy as compared to radiation alone (median: 13.5 ng/ml vs. 8.8 ng/ml, p = 0.003). Biochemical no-evidence of disease (bNED) survival for all patients was 73% at 3 years. In univariate analysis the following factors were predictive for bNED survival: pre-treatment PSA (< or = 20 ng/ml vs. > 20 ng/ml; 3-years bNED 82% vs. 49%; p < 0.001); age (< 72 years vs. > or = 72 years; 3-years bNED 69% vs. 78%; p = 0.049); tumor differentiation (grade 1 vs. grade 2 vs. grade 3; 3-years bNED 89% vs. 74% vs. 46%; p = 0.002); PSA-nadir value (< or = 0.5 ng/ml vs. > 0.5 ng/ml; 3-years bNED 84% vs. 51%; p < 0.001); time to PSA-nadir (< or = 12 months vs. > 12 months; 3-years bNED 66% vs. 82%; p = 0.04). There was a trend to a lower bNED survival in patients with T3/T4 disease (T1/T2 vs. T3/T4; 3-years bNED 80% vs. 60%; p = 0.059). Neoadjuvant hormonal therapy or dose to the prostate had no significant impact on bNED survival. In multivariate analysis pretreatment PSA, tumor differentiation, PSA-nadir, time to PSA-nadir and age were independent prognostic factors.
CONCLUSIONS: Despite of having higher initial PSA-values patients treated with conformal radiotherapy and short-term neoadjuvant hormonal therapy had the same bNED survival as patients treated with conformal radiotherapy alone. Patients with initial PSA values above 20 ng/ml, with T3 or T4 disease or with poorly differentiated tumors had a low biochemical control. For this group of patients intensified therapy should be considered.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app